Balboa Wealth Partners Acquires 480 Shares of Pfizer Inc. (NYSE:PFE)

Balboa Wealth Partners lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,678 shares of the biopharmaceutical company’s stock after purchasing an additional 480 shares during the quarter. Balboa Wealth Partners’ holdings in Pfizer were worth $814,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth $26,000. Gladius Capital Management LP increased its position in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at about $28,000. Finally, Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter worth about $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.0 %

Shares of NYSE PFE opened at $25.73 on Thursday. The stock has a market cap of $145.79 billion, a P/E ratio of 18.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm has a 50 day moving average price of $26.28 and a two-hundred day moving average price of $27.18. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.